Recruiting
Phase 2

Neoadjuvant Agents

Sponsor:

QuantumLeap Healthcare Collaborative

Code:

NCT01042379

Conditions

Breast Neoplasms

Breast Cancer

Breast Tumors

Angiosarcoma

TNBC - Triple-Negative Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Standard Therapy

AMG 386 with or without Trastuzumab

AMG 479 (Ganitumab) plus Metformin

MK-2206 with or without Trastuzumab

AMG 386 and Trastuzumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-04. This information was provided to ClinicalTrials.gov by QuantumLeap Healthcare Collaborative on 2025-08-06.